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Sir,
In their recent article, Martello et al (2010) have shown that the
miR-103/107 microRNA family downregulates global miRNA
biogenesis by targeting the expression of the miRNA-processing
endonuclease Dicer. They further show that Dicer downregulation
leads to an epithelial-mesenchymal transition (EMT) and metas-
tasis. Although Martello et al (2010) successfully elucidated a
mechanism of Dicer downregulation, in this correspondence
we extend our previous work (Grelier et al, 2009), and attempt
to bring the field further by addressing several new questions and
showing new results.
The novelty of the association of decreased Dicer expression with
EMT and mesenchymal phenotype is questionable considering our
previous published work. Using 21 breast cancer cell lines, two
cellular models of human and mouse mammary cancer progression,
and human cohort data, we had shown previously a significant
downregulation of Dicer expression when cells exhibit mesenchymal
phenotypes (Grelier et al, 2009). Using RT-qPCR and western
blotting, we assessed Dicer expression in two distinct bone metastasis
subpopulations derived from MDA-MB-231 breast cancer cells and
found it to be significantly decreased in the two independent clones.
Also, our examination of a cohort of breast cancer patients revealed
significantly lower 8-year metastasis-free survival from primary
tumours exhibiting lower Dicer cDNA levels.
As levels of the full-length protein were decreased with
mesenchymal phenotypes, we wondered about the deregulated
miRNAs targeting the Dicer 30UTR during EMT, as it was already
published that this region contains multiple different miRNA
target sites. Dicer mRNA presents several let-7 target sequences,
both in the coding region and in its 30UTR (Figure 1A), diff-
erentially affecting its protein expression (Forman et al, 2008).
Such a negative feedback regulation was shown on Dicer-Like1
expression in Arabidopsis (Xie et al, 2003). Also, Asirvatham
et al (2008) had previously shown, using multiple compu-
tational prediction tools, that the Dicer 30UTR contains several
miR-103/107 target sites. Using TargetScan, we have now found 27
different miRNA target sites in the 30UTR, with five corresponding
to the miR-103/107 (Figure 1A).
In addition to regulation via its long 30UTR, mammalian Dicer
mRNA appears as multiple spliced isoforms exhibiting 50 and 30
end truncations. We previously described 14 putative variants in
human Dicer mRNA (Grelier et al, 2009). Notably, three variants
encode the full-length protein, but only variants a and b exhibit
the long 30UTR sequence, while variant c has a very short 30UTR
lacking all predicted miRNA target sites (Figure 1A). We also
identified two truncated forms, variants d and e (Figure 1A), whose
expression vary greatly among different breast cancer cell lines
(Figure 1B and data not shown). These two forms, respectively,
encode a protein of 113kDa and a protein of 92.7kDa, which retain
the ribonuclease III functional domains (Figure 1A). Variant d
exhibits a 30UTR sequence composed of a partial intron 23 and
variant e has a very short 30UTR sequence (30 bases), neither with
any described miRNA binding sites. Here, we have shown that the
presence of these spliced forms correlated with breast cancer
staging subtypes and epithelial/mesenchymal phenotype
(Figure 1B). Indeed, in almost all cell lines we examined
that exhibit a complete or partial mesenchymal phenotype, these
truncated isoforms were not detectable by western blot. Con-
versely, and without exception, epithelial cells expressed readily
detectable levels of the two variants (Figure 1B). The absence of
variants d and e correlated with basal cancer subtype cells; all
luminal A subtype cells showed expression of the two alternative
proteins; luminal B subtype cells showed higher expression of
variant e (Figure 1B and data not shown). Furthermore, we have
found decreased expression of variants d and e during EMT using
immortalised human epithelial mammary cells transfected by RAS
(Figure 1C). These data imply an integral role for internal
site miRNA regulation of Dicer isoforms, but the physiological
relevance of these data remains to be clarified.
In contrast to our results, Martello et al (2010) were not able to
find Dicer mRNA expression associated with metastatic relapse in
breast cancers, while they have shown an association between
high levels of miR-103/107 and poor prognosis. In our study, Dicer
mRNA expression was investigated by RT-qPCR using primers
that specifically amplify the three full-length variants and not by
transcriptomic microarrays that do not discriminate between these
diverse forms of Dicer. Because variant c is insensitive to miRNA
that targets 30UTR, this could explain the discrepancy between
30UTR-targeted Dicer downregulation and the high levels detected
of mature miR-103/107. However, variant c can still be targeted by Published online 30 November 2010
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computational evidence, may lead to mRNA degradation (Forman
et al, 2008). As two out of the three coding region let-7 binding
sites are present on the Dicer variants a, b, c, d and e, this route
cannot be ignored.
Many questions remain unaddressed with regard to Dicer
mRNA regulation. What is the relevance of the Dicer and
miR-103/107 expression relationship in vivo where Dicer exists
as multiple mRNA isoforms and can be targeted by multiple
miRNAs? Is there a competition between the different miRNAs in
binding their targets as some miRNA consensus sequences
overlap? Is there a competition between miRNA binding and the
HuR RNA binding protein also present in 30UTR of Dicer?
In summary, both our results (Grelier et al, 2009) and those of
Martello et al (2010) show that Dicer downregulation is associated
with EMT, a process that appears central to metastasis. Here we
provide new results highlighting the complexity of Dicer expres-
sion regulation in breast cancer progression.
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Figure 1 (A) Schematic representation of five Dicer mRNA variants and the corresponding proteins. Using AceView (http://www.AceView.org),
transcription from the Dicer gene putatively produces 14 mRNAs, 11 alternatively spliced variants and 3 full-length forms. The cartoon shows the three
full-length mRNA variants (a, b and c) and the corresponding full-length protein (218kDa) and the two alternatively spliced variants (d and e) and their
corresponding proteins (respectively, 113 and 93kDa). For the mRNA, alternating colours indicate the different exons and grey bars represent 50 and
30UTRs. Domain structures are represented on proteins: green areas represent the ribonuclease domains, grey areas represent the dsRNA binding domain,
and light green areas represent the helicase C domain. k indicates miR-103/107 target sites in the 30UTR region, *indicates let-7 target sites in the coding
and 30UTR regions. 30UTR variant a is 4269 bases long, 30UTR variant b is 4270 bases long, 30UTR variant c is 175 bases long and contains no miRNA target
sites and **indicates two let-7 sites. The 30UTR of variant d is 431 bases long (corresponding to the partial intron 23 sequence) and the 30UTR of variant e is
30 bases long (with no miRNA target sites). (B) Expression of full-length Dicer protein and dþe isoforms in breast cancer cell lines. Western blot analysis of
full-length and truncated variant isoforms of Dicer levels in 10 breast cancer cell lines. Actin was used as a loading control. (C) Expression of full-length Dicer
and d and e isoform proteins during EMT. Western blot analysis of Dicer expression in HMECþhTERT (immortalised human mammary epithelial cells
stably expressing hTERT) cell line and in HMECþhTERTþRAS (immortalised HMECþhTERT transfected with RAS oncogene) cells. Actin was used as a
loading control. (E) indicates epithelial phenotype; (M) indicates mesenchymal phenotype; (E/M) indicates a mixed phenotype.
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